Amsbio reports how researchers at the Graduate School of Medicine, Kyoto University (Japan) have cultured patient-derived colorectal cancer cells in 3D using their MatriMix 511 extracellular matrix (ECM).
In this study** the researchers demonstrated that MatriMix supported robust cancer organoid formation, and that the organoids retained biologically relevant differences between tumour stages. By comparison, alternative matrices evaluated showed limited or no metastatic marker expression. The researchers concluded that MatriMix offers the ability to create models that better reflect in vivo tumour biology and thus is highly relevant for cancer modelling and drug response studies.
Dr Phillip Boder, Cell & Gene Therapy Business Manager for Amsbio commented “Colorectal cancer is one of the commonest types of cancer worldwide, with tens of thousands of deaths per year reported. Although cytotoxic and molecularly targeted drugs have improved the patient survival, it is still challenging to treat metastatic colorectal cancer. The ability of MatriMix to support organoid formation that better reflects patient tumour biology provides a valuable tool for cancer researchers. In addition to improving experimental reproducibility, MatriMix offers superior control of experimental conditions compared to undefined matrices.”
Composed of fully defined collagen type I and III, laminin-511 E8 fragments, and hyaluronic acid, MatriMix is a ready-to-use 3D culture substrate product optimized for culturing patient derived cancer cells.
For further information on MatriMix please visit https://www.amsbio.com/3d-cell-culture-extracellular-matrices/matrimix or contact Amsbio on +31-72-8080244 / +44-1235-828200 / +1-617-945-5033 / info@amsbio.com. To read the University of Kyoto study** in full please visit https://aacrjournals.org/mct/article/17/10/2187/272549/A-Chemosensitivity-Study-of-Colorectal-Cancer
